Galapagos Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Paul Stoffels

Algemeen directeur

€2.0m

Totale compensatie

Percentage CEO-salaris	38.0%
Dienstverband CEO	2.6yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.5yrs
Gemiddelde ambtstermijn bestuur	2.6yrs

Recente managementupdates

Recent updates

€41.78: That's What Analysts Think Galapagos NV (AMS:GLPG) Is Worth After Its Latest Results

May 06

Here's Why We're Not Too Worried About Galapagos' (AMS:GLPG) Cash Burn Situation

Mar 29

Analyse CEO-vergoeding

Hoe is Paul Stoffels's beloning veranderd ten opzichte van Galapagos's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-€61m
Jun 30 2024	n/a	n/a	€32m
Mar 31 2024	n/a	n/a	€31m
Dec 31 2023	€2m	€750k	-€4m
Sep 30 2023	n/a	n/a	-€153m
Jun 30 2023	n/a	n/a	-€46m
Mar 31 2023	n/a	n/a	-€69m
Dec 31 2022	€1m	€563k	-€71m

Compensatie versus markt: De totale vergoeding ($USD 2.05M ) Paul } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Dutch markt ($USD 1.96M ).

Compensatie versus inkomsten: De vergoeding van Paul is gestegen terwijl het bedrijf verliesgevend is.

CEO

Paul Stoffels (62 yo)

2.6yrs

Tenure

€1,971,286

Compensatie

Dr. Paulus A. Stoffels, also known as Paul, Ph.D. M.D. is Chief Executive Officer of Galapagos NV since April 01, 2022 and also serves as its Chairman since April 26, 2022 and also serves as its Interim He...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Paulus Stoffels	CEO, Chairman	2.6yrs	€1.97m	geen gegevens
Thad Huston	Executive VP	1.3yrs	geen gegevens	geen gegevens
Sofie Van Gijsel	Head of Investor Relations	no data	geen gegevens	geen gegevens
Valeria Cnossen	Executive VP & General Counsel	2.8yrs	geen gegevens	geen gegevens
Marieke Vermeersch	Head of Corporate Communication	no data	geen gegevens	geen gegevens
Annelies Missotten	Executive VP & Chief Human Resources Officer	no data	geen gegevens	geen gegevens
Ellen Aar	Head of Development	no data	geen gegevens	geen gegevens
Philippe Alen	Senior VP & Head of Business Development	2.8yrs	geen gegevens	geen gegevens
Alice Dietrich	Head of Medical Affairs	no data	geen gegevens	geen gegevens
Pierre Raboisson	Head of Small Molecules Discovery & Senior VP	2.4yrs	geen gegevens	geen gegevens
Patrik Ringblom	Head of Strategy & US Lead	1.1yrs	geen gegevens	geen gegevens
Jeevan Shetty	Head of Clinical Development Oncology	no data	geen gegevens	geen gegevens

2.5yrs

Gemiddelde duur

52.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van GLPG wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Paulus Stoffels	CEO, Chairman	2.6yrs	€1.97m	geen gegevens
Simon Sturge	Independent Non-Executive Director	1.2yrs	€32.37k	0.00027% € 4.5k
Jerome Contamine	Lead Independent Non-Executive Director	2.6yrs	€150.00k	0.0015% € 25.6k
Andrew Dickinson	Non-Executive Non-Independent Director	less than a year	geen gegevens	geen gegevens
Linda Higgins	Non-Executive Non-Independent Director	5.1yrs	geen gegevens	geen gegevens
Susanne Schaffert	Non-Executive Independent Director	1.4yrs	€59.85k	0.00055% € 9.2k
Oleg Nodelman	Non-Executive Non-Independent Director	less than a year	geen gegevens	geen gegevens
Peter Guenter	Independent Non-Executive Director	5.6yrs	€115.00k	0.0030% € 50.5k
Elisabeth Svanberg	Independent Non-Executive Director	4.6yrs	€138.75k	0.0029% € 47.8k

2.6yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van GLPG wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.6 jaar), wat duidt op een nieuw bestuur.

Galapagos Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Galapagos NV Announces Board Changes

Galapagos NV Announces Board Changes

Michele Manto to Join Alfasigma and Resigns from His Position as Chief Commercial Officer and Executive Committee Member At Galapagos

High number of new directors

Galapagos NV Announces Board Changes

Galapagos Appoints Thad Huston as Chief Financial Officer, Effective from July 1, 2023

Recent updates

Consensus EPS estimates fall from profit to €1.27 loss

Forecast to breakeven in 2024

New minor risk - Profitability

Galapagos NV to Report First Half, 2025 Results on Jul 23, 2025

Consensus EPS estimates increase by 185%

Consensus EPS estimates fall by 23%

Galapagos NV Announces Board Changes

Consensus EPS estimates fall by 49%

Investor sentiment improves as stock rises 17%

Galapagos Announces FDA Clearance of IND Application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in Relapsed/Refractory Non-Hodgkin Lymphoma

Second quarter 2024 earnings released

Galapagos NV to Report Fiscal Year 2024 Results on Feb 12, 2025

Consensus EPS estimates fall by 10%

Consensus EPS estimates upgraded to €0.72 loss, revenue downgraded

First quarter 2024 earnings released: EPS: €0.36 (vs €0.35 in 1Q 2023)

Galapagos NV (AMS:GLPG) Analysts Are More Bearish Than They Used To Be

Consensus revenue estimates decrease by 11%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Galapagos NV Announces Board Changes

New major risk - Revenue and earnings growth

Galapagos NV to Present New Preliminary Translational Data at EBMT-EHA Annual Meeting 2024

Alfasigma S.p.A. completed the acquisition of Filgotinib business from Galapagos NV (ENXTAM:GLPG).

Consensus EPS estimates fall by 14%

Galapagos NV's (AMS:GLPG) Shares Lagging The Industry But So Is The Business

Michele Manto to Join Alfasigma and Resigns from His Position as Chief Commercial Officer and Executive Committee Member At Galapagos

Galapagos Announces Start of PAPILIO-1 Phase 1/2 Multiple Myeloma Study of Point-Of-Care Manufactured BCMA CAR-T Candidate, GLPG5301

Galapagos Presents New Encouraging Clinical Data from the Ongoing Phase 1/2 CD19 CAR-T Studies with GLPG5201 and GLPG5101

Consensus estimates of losses per share improve by 31%

Consensus estimates of losses per share improve by 13%

Consensus EPS estimates fall by 27%

Galapagos NV to Report First Half, 2024 Results on Aug 01, 2024

Third quarter 2023 earnings released: EPS: €0.39 (vs €0.33 in 3Q 2022)

High number of new directors

Galapagos NV Announces Board Changes

Galapagos NV to Report Q4, 2023 Results on Mar 28, 2024

Galapagos NV Announces Start of Phase 2 Study with Selective Tyk2 Inhibitor, GLPG3667, in Patients with Active Systemic Lupus Erythematosus

Consensus estimates of losses per share improve by 12%

New major risk - Revenue and earnings growth

Galapagos NV Revises Sales Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Lacklustre Performance Is Driving Galapagos NV's (AMS:GLPG) Low P/S

Galapagos Appoints Thad Huston as Chief Financial Officer, Effective from July 1, 2023

Galapagos NV Announces Director Changes

Galapagos to Showcase CAR-T Point-Of-Care Manufacturing and Initial Phase 1/2 CLL Data with CD19 CAR-T Candidate, GLPG5201, at the EHA 2023 Congress

Consensus EPS estimates fall by 30%

Consensus EPS estimates fall by 19%

Consensus EPS estimates upgraded to €2.71 loss, revenue downgraded

€41.78: That's What Analysts Think Galapagos NV (AMS:GLPG) Is Worth After Its Latest Results

First quarter 2023 earnings released: EPS: €0.35 (vs €0.20 loss in 1Q 2022)

Price target decreased by 8.1% to €41.78

Here's Why We're Not Too Worried About Galapagos' (AMS:GLPG) Cash Burn Situation

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to €1.17 loss, revenue downgraded

Full year 2022 earnings released: €3.32 loss per share (vs €1.92 loss in FY 2021)

Price target decreased by 13% to €47.62

Galapagos NV Announces Topline Results from Phase 3 DIVERSITY Trial of Filgotinib in Crohn’s Disease

Consensus EPS estimates fall by 48%

Galapagos NV Announces Changes in the Executive Committee Effective 1 January 2023

Galapagos and CellPoint Presented Encouraging Initial Data AtASH 2022 for GLPG5101, a CD19 CAR-T Candidate Manufactured At Point-Of-Care

Consensus forecasts updated

Price target decreased to €52.86

Consensus estimates of losses per share improve by 84%

Galapagos Announces CHMP Adoption of PRAC’s Recommendation for Jyseleca® Following Extensive Safety Review of all JAK Inhibitors

Galapagos NV to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022

Galapagos NV to Report Fiscal Year 2022 Final Results on Mar 23, 2023

Third quarter 2022 earnings released: EPS: €0.30 (vs €0.99 loss in 3Q 2021)

Galapagos NV to Report Q1, 2023 Results on May 04, 2023

Galapagos Receives Positive CHMP Opinion for Jyseleca® European Label Update Based on Testicular Function Safety Data from MANTA/RAy Studies

Galapagos NV announced that it has received €3.07625 million in funding